Find more clinical trials

Resveratrol for Alzheimer's Disease

Start: May 2012

End: March 2014

Enrollment: 120

What Is This Study About?

The purpose of this study is to determine whether daily resveratrol therapy can delay or alter the deterioration of memory and daily functioning in people with probable Alzheimer's disease.

Do I Qualify To Participate in This Study?

Minimum Age: 50 Years

Maximum Age: N/A

Must have:

++Diagnosis of probable Alzheimer's disease (NINDS-ADRDA criteria)++Age 50 years or older++Able to ingest oral medications++Caregiver/Study Partner who has direct contact with the participant more than 2 days per week to accompany participant to all visits++MMSE score between 14 and 26 (inclusive)++Modified Hachinski score of less than or equal to 4++Able to abstain from ingesting large quantities of resveratrol-containing foods (including red wine); 1-2 glasses of red wine or red grape juice daily acceptable; 1 serving of red grapes daily acceptable++Able to abstain from ingesting herbal/natural preparations or dietary supplements containing resveratrol

Must NOT have:

++Non-Alzheimer's dementia or probable Alzheimer's disease with Down syndrome++History of clinically significant stroke++Current evidence or history in past 2 years of epilepsy, focal brain lesion, head injury with loss of consciousness, or any major psychiatric disorder++Sensory impairment that would preclude the participant from participating in or cooperating with the protocol++Use of investigational agent within 2 months prior to screening++Significant clinical disorder or laboratory finding that renders the participant unsuitable for receiving an investigational drug, including clinically significant or unstable hematologic, hepatic, cardiovascular, pulmonary, gastrointestinal, endocrine, metabolic, renal, or other systemic disease or laboratory abnormality++Active neoplastic disease, history of cancer within 5 years prior to screening (skin melanoma or stable prostate cancer is allowable)++History of seizure within past 5 years++Pregnancy or possible pregnancy

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Arizona
Banner Alzheimer's Institute
Phoenix, 85006
California
University of California, Irvine
Irvine, 92697
University of California, San Diego - Comprehensive Alzheimer's Program
La Jolla, 92037
University of Southern California
Los Angeles, 90033
Connecticut
Yale University
New Haven, 06510
District of Columbia
Georgetown University
Washington, 20057
Howard University
Washington, 20060
Florida
Mayo Clinic, Jacksonville
Jacksonville, 32224
University of South Florida
Tampa, 33613
Illinois
Rush University Medical Center
Chicago, 60612
Kansas
University of Kansas
Kansas City, 66205
Kentucky
University of Kentucky
Lexington, 40504
Maryland
Johns Hopkins University
Baltimore, 21224
Michigan
University of Michigan
Ann Arbor, 48105
Minnesota
Mayo Clinic, Rochester
Rochester, 55905
Nevada
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, 89106
New York
New York University
New York, 10016
Mount Sinai School of Medicine
New York, 10029
Columbia University
New York, 10032
University of Rochester Medical Center
Rochester, 14620
Ohio
Case Western Reserve University
Beachwood, 44122
Pennsylvania
University of Pennsylvania
Philadelphia, 19104
South Carolina
Medical University of South Carolina
N. Charleston, 29406
Texas
University of Texas Southwestern Medical Center
Dallas, 75390
Baylor College of Medicine
Houston, 77030
Washington
U of WA / VA Puget Sound Alzheimer's Disease Research Center
Seattle, 98108

Who Sponsors This Study?

Lead: Alzheimer's Disease Cooperative Study (ADCS)

Source: ClinicalTrials.gov ID: NCT01504854